Serious adverse event: late neurotropic disease associated with yellow fever vaccine
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , |
Tipo de documento: | Relatório |
Idioma: | eng |
Título da fonte: | Einstein (São Paulo) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082020000100507 |
Resumo: | ABSTRACT The yellow fever is a systemic disease that was under control due to the effective campaigns against the vector and promotion of vaccines programs. However, since 1999, outbreaks appeared because of inefficient control of the vector, and led to the need of amplifying the immunization in large scale against the yellow fever virus, and consequently, raising the risk of adverse reactions to the vaccine. We report a case of previously healthy infant, who was referred to our care service, after 3 days with fever, chills, nausea and vomits, he received support therapy and was discharged from the hospital. After 24 hours of supportive measures, he was discharge. The patient returned to our service with general condition decline, strabismus, inability to control of cervical musculature and reduced force of the legs. The patient vaccine had received all vaccines from the calendar, and he was vaccinated for yellow fever 20 days before symptoms. During the hospitalization, liquor was collected, and ceftriaxone and aciclovir were administered. After negative cultures from the liquor, the antibiotics were suspended. The computed tomography of patient’s brain showed no alterations. Research for antibodies against yellow fever was requested, being positive for IgM in the liquor, and confirming the neurotropic disease associated with the yellow fever vaccine. On the fifth day of hospitalization, the patient showed improvement on the strabismus, cervical tonus, and musculature force. On the tenth day of hospitalization, patient showed complete improvement, and his laboratory exams no alterations. Subsequently, patient was discharged. The vaccine against yellow fever is safe, efficient and highly recommended, however it is not completely free from serious adverse reactions, including death. |
id |
IIEPAE-1_9e0ed689efd3b52676cf56d604a1ffdc |
---|---|
oai_identifier_str |
oai:scielo:S1679-45082020000100507 |
network_acronym_str |
IIEPAE-1 |
network_name_str |
Einstein (São Paulo) |
repository_id_str |
|
spelling |
Serious adverse event: late neurotropic disease associated with yellow fever vaccineImmunizationYellow fever vaccineDrug-related side effects and adverse reactionsEncephalomyelitis, acute disseminatedYellow feverChild healthABSTRACT The yellow fever is a systemic disease that was under control due to the effective campaigns against the vector and promotion of vaccines programs. However, since 1999, outbreaks appeared because of inefficient control of the vector, and led to the need of amplifying the immunization in large scale against the yellow fever virus, and consequently, raising the risk of adverse reactions to the vaccine. We report a case of previously healthy infant, who was referred to our care service, after 3 days with fever, chills, nausea and vomits, he received support therapy and was discharged from the hospital. After 24 hours of supportive measures, he was discharge. The patient returned to our service with general condition decline, strabismus, inability to control of cervical musculature and reduced force of the legs. The patient vaccine had received all vaccines from the calendar, and he was vaccinated for yellow fever 20 days before symptoms. During the hospitalization, liquor was collected, and ceftriaxone and aciclovir were administered. After negative cultures from the liquor, the antibiotics were suspended. The computed tomography of patient’s brain showed no alterations. Research for antibodies against yellow fever was requested, being positive for IgM in the liquor, and confirming the neurotropic disease associated with the yellow fever vaccine. On the fifth day of hospitalization, the patient showed improvement on the strabismus, cervical tonus, and musculature force. On the tenth day of hospitalization, patient showed complete improvement, and his laboratory exams no alterations. Subsequently, patient was discharged. The vaccine against yellow fever is safe, efficient and highly recommended, however it is not completely free from serious adverse reactions, including death.Instituto Israelita de Ensino e Pesquisa Albert Einstein2020-01-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082020000100507einstein (São Paulo) v.18 2020reponame:Einstein (São Paulo)instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)instacron:IIEPAE10.31744/einstein_journal/2020rc5041info:eu-repo/semantics/openAccessOliveira,Henrique Souza Barros deAraujo,Patricia Padial deSousa,Jamile Rafaela Poltronieri deDonis,Ana Carolina GaribaMoreira,DeiseMakssoudian,Andreaeng2020-02-17T00:00:00Zoai:scielo:S1679-45082020000100507Revistahttps://journal.einstein.br/pt-br/ONGhttps://old.scielo.br/oai/scielo-oai.php||revista@einstein.br2317-63851679-4508opendoar:2020-02-17T00:00Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)false |
dc.title.none.fl_str_mv |
Serious adverse event: late neurotropic disease associated with yellow fever vaccine |
title |
Serious adverse event: late neurotropic disease associated with yellow fever vaccine |
spellingShingle |
Serious adverse event: late neurotropic disease associated with yellow fever vaccine Oliveira,Henrique Souza Barros de Immunization Yellow fever vaccine Drug-related side effects and adverse reactions Encephalomyelitis, acute disseminated Yellow fever Child health |
title_short |
Serious adverse event: late neurotropic disease associated with yellow fever vaccine |
title_full |
Serious adverse event: late neurotropic disease associated with yellow fever vaccine |
title_fullStr |
Serious adverse event: late neurotropic disease associated with yellow fever vaccine |
title_full_unstemmed |
Serious adverse event: late neurotropic disease associated with yellow fever vaccine |
title_sort |
Serious adverse event: late neurotropic disease associated with yellow fever vaccine |
author |
Oliveira,Henrique Souza Barros de |
author_facet |
Oliveira,Henrique Souza Barros de Araujo,Patricia Padial de Sousa,Jamile Rafaela Poltronieri de Donis,Ana Carolina Gariba Moreira,Deise Makssoudian,Andrea |
author_role |
author |
author2 |
Araujo,Patricia Padial de Sousa,Jamile Rafaela Poltronieri de Donis,Ana Carolina Gariba Moreira,Deise Makssoudian,Andrea |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Oliveira,Henrique Souza Barros de Araujo,Patricia Padial de Sousa,Jamile Rafaela Poltronieri de Donis,Ana Carolina Gariba Moreira,Deise Makssoudian,Andrea |
dc.subject.por.fl_str_mv |
Immunization Yellow fever vaccine Drug-related side effects and adverse reactions Encephalomyelitis, acute disseminated Yellow fever Child health |
topic |
Immunization Yellow fever vaccine Drug-related side effects and adverse reactions Encephalomyelitis, acute disseminated Yellow fever Child health |
description |
ABSTRACT The yellow fever is a systemic disease that was under control due to the effective campaigns against the vector and promotion of vaccines programs. However, since 1999, outbreaks appeared because of inefficient control of the vector, and led to the need of amplifying the immunization in large scale against the yellow fever virus, and consequently, raising the risk of adverse reactions to the vaccine. We report a case of previously healthy infant, who was referred to our care service, after 3 days with fever, chills, nausea and vomits, he received support therapy and was discharged from the hospital. After 24 hours of supportive measures, he was discharge. The patient returned to our service with general condition decline, strabismus, inability to control of cervical musculature and reduced force of the legs. The patient vaccine had received all vaccines from the calendar, and he was vaccinated for yellow fever 20 days before symptoms. During the hospitalization, liquor was collected, and ceftriaxone and aciclovir were administered. After negative cultures from the liquor, the antibiotics were suspended. The computed tomography of patient’s brain showed no alterations. Research for antibodies against yellow fever was requested, being positive for IgM in the liquor, and confirming the neurotropic disease associated with the yellow fever vaccine. On the fifth day of hospitalization, the patient showed improvement on the strabismus, cervical tonus, and musculature force. On the tenth day of hospitalization, patient showed complete improvement, and his laboratory exams no alterations. Subsequently, patient was discharged. The vaccine against yellow fever is safe, efficient and highly recommended, however it is not completely free from serious adverse reactions, including death. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/report |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
report |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082020000100507 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082020000100507 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.31744/einstein_journal/2020rc5041 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Instituto Israelita de Ensino e Pesquisa Albert Einstein |
publisher.none.fl_str_mv |
Instituto Israelita de Ensino e Pesquisa Albert Einstein |
dc.source.none.fl_str_mv |
einstein (São Paulo) v.18 2020 reponame:Einstein (São Paulo) instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE) instacron:IIEPAE |
instname_str |
Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE) |
instacron_str |
IIEPAE |
institution |
IIEPAE |
reponame_str |
Einstein (São Paulo) |
collection |
Einstein (São Paulo) |
repository.name.fl_str_mv |
Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE) |
repository.mail.fl_str_mv |
||revista@einstein.br |
_version_ |
1752129910477946880 |